Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines—An Institution-Based, Open-Label, Single-Group Longitudinal Trial
Background: Bilastine 20 mg daily is a second-generation antihistamine (sgAH) approved for chronic spontaneous urticaria (CSU). Up-dosing to 40 or 80 mg daily is recommended in uncontrolled patients. Aim and Objectives: Evaluating the effectiveness, safety, and tolerability of bilastine at 20, 40, a...
محفوظ في:
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wolters Kluwer Medknow Publications
2026-03-01
|
| سلاسل: | Indian Dermatology Online Journal |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://journals.lww.com/10.4103/idoj.idoj_7_25 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|